title: Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7.
abstract: OBJECTIVE
  To define specific staining patterns for the adhesion/growth-regulatory lectin tandem-repeat-type galectin-8 in hypopharyngeal and laryngeal tumor progression and relate these parameters to galectins 1, 3 and 7 in the quest to explore the galectin network.
  
  
  METHODS
  The level of expression of galectin-8 was determined immunohistochemically in a series of 18 and 16 cases of tumor-free epithelium, 24 and 10 cases of low-grade dysplasia, 22 and 15 cases of high-grade dysplasia located in peri-tumoral area of 74 and 37 hypopharyngeal and laryngeal carcinomas.
  
  
  RESULTS
  Marked upregulation in galectin-8 staining intensity and immunopositive area in malignancy versus dysplasia was seen in hypopharyngeal cancer (p<10(-6)), in laryngeal cancer for labeling index and high-grade dysplasia/carcinoma (p<10(-6)). No correlation to recurrence was delineated.
  
  
  CONCLUSIONS
  The presented data revealed a divergence within the galectin-1, -3, -7 and -8 network during tumor progression.
authors.affiliation: Laboratory of Anatomy, Faculty of Medicine and Pharmacy, University of Mons-Hainaut, Pentagone 1B - Avenue du Champ de Mars, 6, B-7000 Mons, Belgium.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Cludts
authors.forename: Christine
authors.initials: C
authors.lastname: Decaestecker
authors.forename: Virginie
authors.initials: V
authors.lastname: Mahillon
authors.forename: Dominique
authors.initials: D
authors.lastname: Chevalier
authors.forename: Herbert
authors.initials: H
authors.lastname: Kaltner
authors.forename: Sabine
authors.initials: S
authors.lastname: André
authors.forename: Myriam
authors.initials: M
authors.lastname: Remmelink
authors.forename: Xavier
authors.initials: X
authors.lastname: Leroy
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Gabius
authors.forename: Sven
authors.initials: S
authors.lastname: Saussez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D037483:Galectin 1 / Q000378:metabolism*; D037502:Galectin 3 / Q000378:metabolism*; D037161:Galectins / Q000276:immunology / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D007124:Immunoenzyme Techniques; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D007830:Larynx / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010614:Pharynx / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D011817:Rabbits; D012189:Retrospective Studies; D015854:Up-Regulation
chemical_list: D037483:Galectin 1; D037502:Galectin 3; D037161:Galectins; C092525:LGALS7 protein, human; C091991:LGALS8 protein, human